FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3164470709> ?p ?o ?g. }

• W3164470709 endingPage "1473" @default.
• W3164470709 startingPage "1472.3" @default.
• W3164470709 abstract "Background: The Coronavirus pandemic caused many consequences on well being, access to care and therapeutic maintenance in patients with chronic diseases. Objectives: To assess the impact of COVID-19 on therapeutic maintenance of patients with Chronic Inflammatory Rheumatic Diseases (CIRD) and to identify related factors to difficulties in access to rheumatologist care during the COVID-19 pandemic. Methods: A cross-sectional study was conducted among patients with rheumatic diseases using a questionnaire providing information on patients and disease characteristics, impact of COVID-19 on access to rheumatologist care and therapeutic maintenance during the confinement. Reasons of therapeutic interruption and of diificulties in access to healthcare were precised. Results: We received answers from 350 patients (female sex of 68%, mean age of 46,1 ± 14,4 years) suffering from Chronic Inflammatory Rheumatic Diseases (CIRD):rheumatic arthritis (RA) (62.3%), spondyloarthropathies (34.3%), and undifferentiated CIRD (3.4%). The global average disease evolution was 12,1 ± 9,7 years. The patients were treated with conventional Disease-modifying anti-rheumatic drugs (cDMARDs) and biologic Disease-modifying anti-rheumatic drugs (bDMARDs) in respectively 67.4% and 30.6% of cases. Corticosteroids and Nonsteroidal Anti-Inflammatories (NSAIDs) intake was noted in 39.1 and 33.7% of patients. Difficulties to access to rheumatologist care appointments were reported in 82.9% of the participants. Reasons of thoses difficulties are summurized in Figure 1. Figure 1. Causes of difficulties of access to Rheumatologist care during COVID-19 pandemic. Half of patients declared that the pandemic had affected their therapeutic compliance. Discontinued drugs were in decreasing order: Synthetic antimalarials (68.4%), NSAIDs (45.8%), Methotrexate (43.8%), bDMARDs (25.2%), Sulfasalazine (18.2%) and Corticosteroids (10,2%). Causes of treatments interruption are summarized in Table I. Table 1. Causes of treatments interuption in patients with CIRD Drugs Not found in pharmacies The pharmacy refuses to give me the treatment without a recent prescription To avoid the decrease in immunity and therefore to avoid catching Covid-19 I stopped the follow-up, and so I stopped the treatment... Other reasons NSAIDS 0 27.8 74.1 44.4 27.8 Corticosteroids 0 14.3 92.9 57.1 50 Methotrexate 70.1 3 10.4 16.4 22.4 Sulfasalazine 0 12.5 25 75 100 Synthetic antimalarial 69.2 0 0 23.1 61.5 Leflunomide 0 0 0 0 0 bDMARDs 0 7.4 40.7 44.4 51.9 Conclusion: The COVID-19 pandemic impacted heavly on therapeutic maintenance in CIRD patients in our country. Patients expressed many difficulties in access to appropiate management. Facing to all thoses consequences, we need to devolopp as soon as possible adequate solutions adapted in such health crisis, especially therapeutic education and telemedecine. Disclosure of Interests: None declared" @default.
• W3164470709 created "2021-06-07" @default.
• W3164470709 creator A5007004243 @default.
• W3164470709 creator A5008275294 @default.
• W3164470709 creator A5019652348 @default.
• W3164470709 creator A5023792659 @default.
• W3164470709 creator A5024787999 @default.
• W3164470709 creator A5041468862 @default.
• W3164470709 creator A5068044637 @default.
• W3164470709 creator A5069365413 @default.
• W3164470709 creator A5071855267 @default.
• W3164470709 creator A5074334632 @default.
• W3164470709 creator A5084186058 @default.
• W3164470709 date "2021-05-19" @default.
• W3164470709 modified "2023-09-25" @default.
• W3164470709 title "AB0899-HPR THE IMPACT OF CORONAVIRUS (COVID-19) PANDEMIC ON THERAPEUTIC MAINTENANCE IN PATIENTS WITH CHRONIC INFLAMMATORY RHEUMATIC DISEASES" @default.
• W3164470709 doi "https://doi.org/10.1136/annrheumdis-2021-eular.4151" @default.
• W3164470709 hasPublicationYear "2021" @default.
• W3164470709 type Work @default.
• W3164470709 sameAs 3164470709 @default.
• W3164470709 citedByCount "0" @default.
• W3164470709 crossrefType "journal-article" @default.
• W3164470709 hasAuthorship W3164470709A5007004243 @default.
• W3164470709 hasAuthorship W3164470709A5008275294 @default.
• W3164470709 hasAuthorship W3164470709A5019652348 @default.
• W3164470709 hasAuthorship W3164470709A5023792659 @default.
• W3164470709 hasAuthorship W3164470709A5024787999 @default.
• W3164470709 hasAuthorship W3164470709A5041468862 @default.
• W3164470709 hasAuthorship W3164470709A5068044637 @default.
• W3164470709 hasAuthorship W3164470709A5069365413 @default.
• W3164470709 hasAuthorship W3164470709A5071855267 @default.
• W3164470709 hasAuthorship W3164470709A5074334632 @default.
• W3164470709 hasAuthorship W3164470709A5084186058 @default.
• W3164470709 hasBestOaLocation W31644707091 @default.
• W3164470709 hasConcept C126322002 @default.
• W3164470709 hasConcept C160735492 @default.
• W3164470709 hasConcept C162324750 @default.
• W3164470709 hasConcept C1862650 @default.
• W3164470709 hasConcept C2777575956 @default.
• W3164470709 hasConcept C2779123688 @default.
• W3164470709 hasConcept C2779134260 @default.
• W3164470709 hasConcept C3008058167 @default.
• W3164470709 hasConcept C50522688 @default.
• W3164470709 hasConcept C524204448 @default.
• W3164470709 hasConcept C71924100 @default.
• W3164470709 hasConcept C89623803 @default.
• W3164470709 hasConceptScore W3164470709C126322002 @default.
• W3164470709 hasConceptScore W3164470709C160735492 @default.
• W3164470709 hasConceptScore W3164470709C162324750 @default.
• W3164470709 hasConceptScore W3164470709C1862650 @default.
• W3164470709 hasConceptScore W3164470709C2777575956 @default.
• W3164470709 hasConceptScore W3164470709C2779123688 @default.
• W3164470709 hasConceptScore W3164470709C2779134260 @default.
• W3164470709 hasConceptScore W3164470709C3008058167 @default.
• W3164470709 hasConceptScore W3164470709C50522688 @default.
• W3164470709 hasConceptScore W3164470709C524204448 @default.
• W3164470709 hasConceptScore W3164470709C71924100 @default.
• W3164470709 hasConceptScore W3164470709C89623803 @default.
• W3164470709 hasIssue "Suppl 1" @default.
• W3164470709 hasLocation W31644707091 @default.
• W3164470709 hasOpenAccess W3164470709 @default.
• W3164470709 hasPrimaryLocation W31644707091 @default.
• W3164470709 hasRelatedWork W2010260295 @default.
• W3164470709 hasRelatedWork W2075863146 @default.
• W3164470709 hasRelatedWork W2156283049 @default.
• W3164470709 hasRelatedWork W2316954211 @default.
• W3164470709 hasRelatedWork W2501908007 @default.
• W3164470709 hasRelatedWork W3015785605 @default.
• W3164470709 hasRelatedWork W3030920657 @default.
• W3164470709 hasRelatedWork W3048464972 @default.
• W3164470709 hasRelatedWork W4249342726 @default.
• W3164470709 hasRelatedWork W4381571638 @default.
• W3164470709 hasVolume "80" @default.
• W3164470709 isParatext "false" @default.
• W3164470709 isRetracted "false" @default.
• W3164470709 magId "3164470709" @default.
• W3164470709 workType "article" @default.